Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKD
Question
Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKD
Direct answer
Demonstrated 42.7% UACR reduction de-risks pivotal Phase II/III AMPLITUDE study approval, securing VRTX's non-CF revenue diversification pipeline. — bullish pressure on VRTX via pipeline net present value addition on AMKD clinical validation.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-24
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKD”, revision 1, evidence through 2026-09-24. https://marketontology.com/catalysts/2026-09-24/vertex-reports-phase-iib-data-for-inaxaplin-with-42-7-proteinuria-drop-in-amkd-cfb5eb
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| VRTX | ▲Bull | 1–4 weeks | pipeline net present value addition on AMKD clinical validation | 62 |
Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKD
Demonstrated 42.7% UACR reduction de-risks pivotal Phase II/III AMPLITUDE study approval, securing VRTX's non-CF revenue diversification pipeline. — bullish pressure on VRTX via pipeline net present value addition on AMKD clinical validation.
Source shows inaxaplin reduced UACR by 42.7% in Phase IIb with AMPLITUDE pivotal enrollment complete.
- SourceSource shows inaxaplin reduced UACR by 42.7% in Phase IIb with AMPLITUDE pivotal enrollment complete.
- TransmissionDemonstrated 42.7% UACR reduction de-risks pivotal Phase II/III AMPLITUDE study approval, securing VRTX's non-CF revenue diversification pipeline.
- SummaryVertex posted positive Phase IIb results for kidney candidate inaxaplin, showing a 42.7% UACR reduction in AMKD. Enrollment is now complete in the Phase II/III AMPLITUDE pivotal registration trial.
- VRTXDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- VRTX closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- VRTX price vs. pre-event level
- VRTX volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| VRTX | Bullishdisagreed | 522.38 2026-09-24 | +0.73% | -2.99% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Vertex Posts Positive Phase II Data on Kidney Disease Drug · financial_press · 2026-09-23
Related catalysts
- 2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinVRTX-2.99%
- 2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.